Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice | Zendy

Koung Li Kim | Zendy; Wonhee Suh | Zendy

Open Access

Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice

Author(s) -

Koung Li Kim,

Wonhee Suh

Publication year - 2017

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.17-21416

Subject(s) - apatinib , choroidal neovascularization , vascular endothelial growth factor , neovascularization , medicine , kinase insert domain receptor , angiogenesis , retinal , cancer research , retina , vascular endothelial growth factor a , retinopathy , pathology , ophthalmology , endocrinology , biology , vegf receptors , cancer , neuroscience , diabetes mellitus

Vascular endothelial growth factor (VEGF) signaling via VEGF receptor 2 (VEGFR2) plays a crucial role in pathologic ocular neovascularization. In this study, we investigated the antiangiogenic effect of apatinib, a pharmacologic inhibitor of VEGFR2 tyrosine kinase, against oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV) in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research